Walleye Capital’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$971K Sell
20,643
-14,842
-42% -$367K ﹤0.01% 2150
2026
Q1
$671K Buy
+35,485
New +$602K ﹤0.01% 2426
2025
Q4
Sell
-5,737
Closed -$67.6K 4925
2025
Q3
$67.6K Buy
+5,737
New +$53.5K ﹤0.01% 3888
2024
Q3
Sell
-18,487
Closed -$129K 5667
2024
Q2
$133K Buy
+18,487
New +$162K ﹤0.01% 4562

Other funds holding DFTX

Walleye Capital's DFTX Position: Q2 2026 in Review

Walleye Capital reduced its Definium Therapeutics (DFTX) stake by 42% in Q2 2026, selling an estimated $367K and leaving 20,643 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

Walleye Capital first reported a position in DFTX in Q2 2024 and has held it in 4 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Walleye Capital held 20,643 shares of Definium Therapeutics worth $971K as of Q2 2026.
  • Walleye Capital sold 14,842 Definium Therapeutics shares in Q2 2026, an estimated $367K.
  • Definium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2150 holding.
  • Walleye Capital first reported a position in Definium Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.